|
Canada-0-Engineering Azienda Directories
|
Azienda News:
- Treatment for HER2-Negative Advanced Breast Cancer - WebMD
If your breast cancer is HER2-negative and advanced, what are your treatment options? Learn how hormonal therapies, chemotherapy, targeted therapies, and immunotherapy may help you
- Treatment of Stage IV (Metastatic) Breast Cancer
Systemic (drug) treatments for stage IV breast cancer Treatment often continues until the cancer starts growing again or until side effects become unacceptable If this happens, other drugs might be tried The types of drugs used for stage IV breast cancer depend on the hormone receptor status, the HER2 status of the cancer, and sometimes gene mutations that might be found Hormone receptor
- HER2-Negative Breast Cancer: Meaning Treatment
HER2-negative breast cancer involves having cancerous cells in your breast that don’t contain high levels of the protein human epidermal growth factor 2 (HER2) With most breast cancers, hormones and or the HER2 protein fuel cancer growth For example, with HER2-positive breast cancer, excess HER2 leads to cancerous tumors
- Treatment for hormone receptor-positive, HER2-negative advanced breast . . .
ET alone or in combination with targeted for metastatic hormone receptor-positive, HER2-negative breast cancer is presented here The treatment of HER2-positive disease is discussed elsewhere, as is chemotherapy for ET-resistant, metastatic hormone receptor-positive breast cancer
- NCCN Guidelines Updates: Management of Patients With HER2-Negative . . .
Treatment for metastatic HER2-negative breast cancer is becoming increasingly individualized as more of the tumor landscape is described and drugs are developed to target its pathways Survival can be prolonged by CDK4 6 inhibitors in patients with hormone receptor–positive tumors and by immunotherapy in those with triple-negative disease In patients with BRCA1 2 mutations, PARP inhibitors
- Expert consensus on treating HR+ HER2- metastatic breast cancer based . . .
Hormone receptor-positive, HER2-negative metastatic breast cancer (HR+ HER2-mBC) is incurable, but recent progress has been made in developing new treatment options and the treatment landscape is rapidly shifting There are published recommendations for treatment choices and sequencing to help guide oncologists in treating HR+ HER2-mBC, but little evidence has been published regarding real
- Advancing Treatment After CDK4 6 Inhibitor Progression in HR+ HER2 . . .
The efficacy of contemporary cancer treatments can be attributed to novel targeted and immunotherapeutic agents capable of selectively targeting cancer cells, such as CDK4 6 inhibitors, a hallmark treatment for patients with hormone receptor-positive (HR+) HER2-negative (HER2–) metastatic breast cancer
- FOURLIGHT-1 Study Data Support Atirmociclib for HR+ HER2- Breast Cancer
Patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ HER2-) advanced or metastatic breast cancer whose disease progressed after previous treatment may have a new therapeutic option on the horizon
- Treatment for Breast Cancer - NCI
Many treatments are available for breast cancer Learn about local and systemic treatments and access in-depth information about each type of treatment
- FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated . . .
Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
|
|